EyeCyte Gets Funding

San Diego-based EyeCyte, a firm developing products for the treatment of retinal disease, said Monday that it has raised a Series A funding round from Pfizer. The deal was worth $3M. EyeCyte said that its technology is based on research from The Scripps Research Institute in La Jolla. The firm is developing treatments for retinal diseases, including diabetic retinopathy, retinopathy of prematurity, retinal vascular occlusive disease, age-related macular degeneration (AMD) and retinitis pigmentosa. More information »